{
  "DOI": "10.1186/s40246-023-00546-9",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00546-9",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eDespite a growing number of publications highlighting the potential impact on the therapy outcome, rare genetic variants (minor allele frequency \u0026lt; 1%) in genes associated to drug adsorption, distribution, metabolism, and elimination are poorly studied. Previously, rare germline \u003cjats:italic\u003eDPYD\u003c/jats:italic\u003e missense variants were shown to identify a subset of fluoropyrimidine-treated patients at high risk for severe toxicity. Here, we investigate the impact of rare genetic variants in a panel of 54 other fluoropyrimidine-related genes on the risk of severe toxicity.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eMethods\u003c/jats:title\u003e\n                \u003cjats:p\u003eThe coding sequence and untranslated regions of 54 genes related to fluoropyrimidine pharmacokinetics/pharmacodynamics were analyzed by next-generation sequencing in 120 patients developing grade 3–5 toxicity (NCI-CTC vs3.0) and 104 matched controls. Sequence Kernel Association Test (SKAT) analysis was used to select genes with a burden of genetic variants significantly associated with risk of severe toxicity. The statistical association of common and rare genetic variants in selected genes was further investigated. The functional impact of genetic variants was assessed using two different in silico prediction tools (Predict2SNP; ADME Prediction Framework).\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eSKAT analysis highlighted \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e and \u003cjats:italic\u003ePPARD\u003c/jats:italic\u003e as genes with a genetic mutational burden significantly associated with risk of severe fluoropyrimidine-related toxicity (Bonferroni adjusted \u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.024 and \u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.039, respectively). Looking more closely at allele frequency, the burden of rare \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e variants was significantly higher in patients with toxicity compared with controls (\u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.047, Mann–Whitney test). Carrying at least one rare \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e variant was associated with an approximately fourfold higher risk of severe cumulative (OR = 4.08, \u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.030) and acute (OR = 4.21,\u003cjats:italic\u003e P\u003c/jats:italic\u003e = 0.082) toxicity. The burden of \u003cjats:italic\u003ePPARD\u003c/jats:italic\u003e rare genetic variants was not significantly related to toxicity. Some common variants with predictive value in \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e and \u003cjats:italic\u003ePPARD\u003c/jats:italic\u003e were also identified: \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e rs143004875-T and \u003cjats:italic\u003ePPARD\u003c/jats:italic\u003e rs2016520-T variants predicted an increased risk of severe cumulative (\u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.002 and \u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.001, respectively) and acute (\u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.005 and\u003cjats:italic\u003e P\u003c/jats:italic\u003e = 0.0001, respectively) toxicity.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusion\u003c/jats:title\u003e\n                \u003cjats:p\u003eThis work demonstrated that the rare mutational burden of \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e, a gene strictly cooperating with \u003cjats:italic\u003eDPYD\u003c/jats:italic\u003e in the catabolic pathway of fluoropyrimidines, is a promising pharmacogenetic marker for precision dosing of fluoropyrimidines. Additionally, some common genetic polymorphisms in \u003cjats:italic\u003eDPYS\u003c/jats:italic\u003e and \u003cjats:italic\u003ePPARD\u003c/jats:italic\u003e were identified as promising predictive markers that warrant further investigation.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "546"
  ],
  "article-number": "99",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "3 October 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "26 October 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "9 November 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "See the “Patient cohorts and Clinical Data Collection” section."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "The authors declare no conflict of interest."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "De Mattia",
      "given": "Elena",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Polesel",
      "given": "Jerry",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Silvestri",
      "given": "Marco",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Roncato",
      "given": "Rossana",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Scarabel",
      "given": "Lucia",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Calza",
      "given": "Stefano",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Spina",
      "given": "Michele",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Puglisi",
      "given": "Fabio",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Toffoli",
      "given": "Giuseppe",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cecchin",
      "given": "Erika",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        11,
        9
      ]
    ],
    "date-time": "2023-11-09T10:02:09Z",
    "timestamp": 1699524129000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        11,
        9
      ]
    ],
    "date-time": "2023-11-09T10:09:27Z",
    "timestamp": 1699524567000
  },
  "funder": [
    {
      "name": "Italian Ministry of Health (Ricerca Corrente)."
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        14
      ]
    ],
    "date-time": "2024-03-14T11:03:48Z",
    "timestamp": 1710414228442
  },
  "is-referenced-by-count": 2,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        11,
        9
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            11,
            9
          ]
        ],
        "date-time": "2023-11-09T00:00:00Z",
        "timestamp": 1699488000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            11,
            9
          ]
        ],
        "date-time": "2023-11-09T00:00:00Z",
        "timestamp": 1699488000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00546-9.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00546-9/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00546-9.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        11,
        9
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        11,
        9
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1158/1078-0432.CCR-14-1758",
      "author": "M Apellaniz-Ruiz",
      "doi-asserted-by": "publisher",
      "first-page": "322",
      "issue": "2",
      "journal-title": "Clin Cancer Res",
      "key": "546_CR1",
      "unstructured": "Apellaniz-Ruiz M, Lee MY, Sanchez-Barroso L, Gutierrez-Gutierrez G, Calvo I, Garcia-Estevez L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res. 2015;21(2):322–8. https://doi.org/10.1158/1078-0432.CCR-14-1758.",
      "volume": "21",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.biopha.2022.113644",
      "author": "E De Mattia",
      "doi-asserted-by": "publisher",
      "first-page": "113644",
      "journal-title": "Biomed Pharmacother",
      "key": "546_CR2",
      "unstructured": "De Mattia E, Silvestri M, Polesel J, Ecca F, Mezzalira S, Scarabel L, et al. Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk. Biomed Pharmacother. 2022;154:113644. https://doi.org/10.1016/j.biopha.2022.113644.",
      "volume": "154",
      "year": "2022"
    },
    {
      "DOI": "10.1161/CIRCGEN.121.003391",
      "author": "B Gray",
      "doi-asserted-by": "publisher",
      "first-page": "e003391",
      "issue": "1",
      "journal-title": "Circ Genom Precis Med",
      "key": "546_CR3",
      "unstructured": "Gray B, Baruteau AE, Antolin AA, Pittman A, Sarganas G, Molokhia M, et al. Rare variation in drug metabolism and long QT genes and the genetic susceptibility to acquired long QT syndrome. Circ Genom Precis Med. 2022;15(1):e003391. https://doi.org/10.1161/CIRCGEN.121.003391.",
      "volume": "15",
      "year": "2022"
    },
    {
      "DOI": "10.1101/gr.129668.111",
      "author": "LB Ramsey",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Genome Res",
      "key": "546_CR4",
      "unstructured": "Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012;22(1):1–8. https://doi.org/10.1101/gr.129668.111.",
      "volume": "22",
      "year": "2012"
    },
    {
      "DOI": "10.1002/ijc.32898",
      "author": "Q Xiao",
      "doi-asserted-by": "publisher",
      "first-page": "2475",
      "issue": "9",
      "journal-title": "Int J Cancer",
      "key": "546_CR5",
      "unstructured": "Xiao Q, Zhou Y, Winter S, Buttner F, Schaeffeler E, Schwab M, et al. Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients. Int J Cancer. 2020;146(9):2475–87. https://doi.org/10.1002/ijc.32898.",
      "volume": "146",
      "year": "2020"
    },
    {
      "DOI": "10.1038/gim.2016.33",
      "author": "M Kozyra",
      "doi-asserted-by": "publisher",
      "first-page": "20",
      "issue": "1",
      "journal-title": "Genet Med",
      "key": "546_CR6",
      "unstructured": "Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–9. https://doi.org/10.1038/gim.2016.33.",
      "volume": "19",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s40246-018-0157-3",
      "author": "M Ingelman-Sundberg",
      "doi-asserted-by": "publisher",
      "first-page": "26",
      "issue": "1",
      "journal-title": "Hum Genomics",
      "key": "546_CR7",
      "unstructured": "Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genomics. 2018;12(1):26. https://doi.org/10.1186/s40246-018-0157-3.",
      "volume": "12",
      "year": "2018"
    },
    {
      "DOI": "10.1002/cpt.2069",
      "author": "JE Knikman",
      "doi-asserted-by": "publisher",
      "first-page": "591",
      "issue": "3",
      "journal-title": "Clin Pharmacol Ther",
      "key": "546_CR8",
      "unstructured": "Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther. 2021;109(3):591–604. https://doi.org/10.1002/cpt.2069.",
      "volume": "109",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.ejca.2015.11.008",
      "author": "C Lunenburg",
      "doi-asserted-by": "publisher",
      "first-page": "40",
      "journal-title": "Eur J Cancer",
      "key": "546_CR9",
      "unstructured": "Lunenburg C, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40–8. https://doi.org/10.1016/j.ejca.2015.11.008.",
      "volume": "54",
      "year": "2016"
    },
    {
      "key": "546_CR10",
      "unstructured": "EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. European Medicines Agency. Published April 30, 2020. Available from: https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Accessed 1 Sept 2023."
    },
    {
      "DOI": "10.1038/s41416-020-01084-0",
      "author": "Y Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "1782",
      "issue": "12",
      "journal-title": "Br J Cancer",
      "key": "546_CR11",
      "unstructured": "Zhou Y, Dagli Hernandez C, Lauschke VM. Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. Br J Cancer. 2020;123(12):1782–9. https://doi.org/10.1038/s41416-020-01084-0.",
      "volume": "123",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.drup.2018.07.001",
      "author": "E Cecchin",
      "doi-asserted-by": "publisher",
      "first-page": "18",
      "journal-title": "Drug Resist Updat",
      "key": "546_CR12",
      "unstructured": "Cecchin E, De Mattia E, Ecca F, Toffoli G. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18–40. https://doi.org/10.1016/j.drup.2018.07.001.",
      "volume": "39",
      "year": "2018"
    },
    {
      "DOI": "10.1002/ijc.29654",
      "author": "G Toffoli",
      "doi-asserted-by": "publisher",
      "first-page": "2971",
      "issue": "12",
      "journal-title": "Int J Cancer",
      "key": "546_CR13",
      "unstructured": "Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137(12):2971–80. https://doi.org/10.1002/ijc.29654.",
      "volume": "137",
      "year": "2015"
    },
    {
      "key": "546_CR14",
      "unstructured": "Babraham Bioinformatics. Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc. Accessed 1 Sept 2023"
    },
    {
      "DOI": "10.1093/bioinformatics/btp324",
      "author": "H Li",
      "doi-asserted-by": "publisher",
      "first-page": "1754",
      "issue": "14",
      "journal-title": "Bioinformatics",
      "key": "546_CR15",
      "unstructured": "Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60. https://doi.org/10.1093/bioinformatics/btp324.",
      "volume": "25",
      "year": "2009"
    },
    {
      "DOI": "10.1093/bioinformatics/bts503",
      "author": "F Garcia-Alcalde",
      "doi-asserted-by": "publisher",
      "first-page": "2678",
      "issue": "20",
      "journal-title": "Bioinformatics",
      "key": "546_CR16",
      "unstructured": "Garcia-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM, Gotz S, Tarazona S, et al. Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics. 2012;28(20):2678–9. https://doi.org/10.1093/bioinformatics/bts503.",
      "volume": "28",
      "year": "2012"
    },
    {
      "key": "546_CR17",
      "unstructured": "PICARD. Available from: http://broadinstitute.github.io/picard. Accessed 1 Sept 2023."
    },
    {
      "DOI": "10.1093/bioinformatics/btq033",
      "author": "AR Quinlan",
      "doi-asserted-by": "publisher",
      "first-page": "841",
      "issue": "6",
      "journal-title": "Bioinformatics",
      "key": "546_CR18",
      "unstructured": "Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841–2. https://doi.org/10.1093/bioinformatics/btq033.",
      "volume": "26",
      "year": "2010"
    },
    {
      "key": "546_CR19",
      "unstructured": "NCBI-dbSNP. Available from: https://www.ncbi.nlm.nih.gov/snp/. Accessed 1 Sept 2023"
    },
    {
      "DOI": "10.1371/journal.pcbi.1004962",
      "author": "J Bendl",
      "doi-asserted-by": "publisher",
      "first-page": "e1004962",
      "issue": "5",
      "journal-title": "PLoS Comput Biol",
      "key": "546_CR20",
      "unstructured": "Bendl J, Musil M, Stourac J, Zendulka J, Damborsky J, Brezovsky J. PredictSNP2: a unified platform for accurately evaluating SNP effects by exploiting the different characteristics of variants in distinct genomic regions. PLoS Comput Biol. 2016;12(5):e1004962. https://doi.org/10.1371/journal.pcbi.1004962.",
      "volume": "12",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41397-018-0044-2",
      "author": "Y Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "115",
      "issue": "2",
      "journal-title": "Pharmacogenomics J",
      "key": "546_CR21",
      "unstructured": "Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 2019;19(2):115–26. https://doi.org/10.1038/s41397-018-0044-2.",
      "volume": "19",
      "year": "2019"
    },
    {
      "key": "546_CR22",
      "unstructured": "Ensembl’s Variant Effect Predictor. Available from: https://www.ensembl.org/info/docs/tools/vep/index.html. Accessed 1 Sept 2023"
    },
    {
      "DOI": "10.1016/j.ajhg.2008.06.024",
      "author": "B Li",
      "doi-asserted-by": "publisher",
      "first-page": "311",
      "issue": "3",
      "journal-title": "Am J Hum Genet",
      "key": "546_CR23",
      "unstructured": "Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet. 2008;83(3):311–21. https://doi.org/10.1016/j.ajhg.2008.06.024.",
      "volume": "83",
      "year": "2008"
    },
    {
      "key": "546_CR24",
      "unstructured": "HaploReg v4.1. Available from: https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php. Accessed 1 Sept 2023"
    },
    {
      "key": "546_CR25",
      "unstructured": "RegulomeDB v2.0. Available from: https://regulomedb.org/regulome-search/. Accessed 1 Sept 2023"
    },
    {
      "DOI": "10.2217/pgs.10.188",
      "author": "FA Muhale",
      "doi-asserted-by": "publisher",
      "first-page": "341",
      "issue": "3",
      "journal-title": "Pharmacogenomics",
      "key": "546_CR26",
      "unstructured": "Muhale FA, Wetmore BA, Thomas RS, McLeod HL. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics. 2011;12(3):341–50. https://doi.org/10.2217/pgs.10.188.",
      "volume": "12",
      "year": "2011"
    },
    {
      "DOI": "10.1371/journal.pone.0124818",
      "author": "M Hiratsuka",
      "doi-asserted-by": "publisher",
      "first-page": "e0124818",
      "issue": "4",
      "journal-title": "PLoS ONE",
      "key": "546_CR27",
      "unstructured": "Hiratsuka M, Yamashita H, Akai F, Hosono H, Hishinuma E, Hirasawa N, et al. Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity. PLoS ONE. 2015;10(4):e0124818. https://doi.org/10.1371/journal.pone.0124818.",
      "volume": "10",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.bcp.2017.06.121",
      "author": "E Hishinuma",
      "doi-asserted-by": "publisher",
      "first-page": "118",
      "journal-title": "Biochem Pharmacol",
      "key": "546_CR28",
      "unstructured": "Hishinuma E, Akai F, Narita Y, Maekawa M, Yamaguchi H, Mano N, et al. Functional characterization of 21 allelic variants of dihydropyrimidinase. Biochem Pharmacol. 2017;143:118–28. https://doi.org/10.1016/j.bcp.2017.06.121.",
      "volume": "143",
      "year": "2017"
    },
    {
      "DOI": "10.1124/dmd.122.001045",
      "author": "E Hishinuma",
      "doi-asserted-by": "publisher",
      "first-page": "165",
      "issue": "2",
      "journal-title": "Drug Metab Dispos",
      "key": "546_CR29",
      "unstructured": "Hishinuma E, Narita Y, Rico EMG, Ueda A, Obuchi K, Tanaka Y, et al. Functional characterization of 12 dihydropyrimidinase allelic variants in japanese individuals for the prediction of 5-fluorouracil treatment-related toxicity. Drug Metab Dispos. 2023;51(2):165–73. https://doi.org/10.1124/dmd.122.001045.",
      "volume": "51",
      "year": "2023"
    },
    {
      "DOI": "10.2217/pgs.15.81",
      "author": "D Kummer",
      "doi-asserted-by": "publisher",
      "first-page": "1367",
      "issue": "12",
      "journal-title": "Pharmacogenomics",
      "key": "546_CR30",
      "unstructured": "Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, et al. Dihydropyrimidinase and beta-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics. 2015;16(12):1367–77. https://doi.org/10.2217/pgs.15.81.",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1111/cas.14553",
      "author": "K Yokoi",
      "doi-asserted-by": "publisher",
      "first-page": "3359",
      "issue": "9",
      "journal-title": "Cancer Sci",
      "key": "546_CR31",
      "unstructured": "Yokoi K, Nakajima Y, Matsuoka H, Shinkai Y, Ishihara T, Maeda Y, et al. Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer. Cancer Sci. 2020;111(9):3359–66. https://doi.org/10.1111/cas.14553.",
      "volume": "111",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S0021-9258(19)70122-7",
      "author": "T Shiotani",
      "doi-asserted-by": "publisher",
      "first-page": "219",
      "issue": "1",
      "journal-title": "J Biol Chem",
      "key": "546_CR32",
      "unstructured": "Shiotani T, Weber G. Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem. 1981;256(1):219–24.",
      "volume": "256",
      "year": "1981"
    },
    {
      "DOI": "10.1517/17425255.2016.1141196",
      "author": "E Cecchin",
      "doi-asserted-by": "publisher",
      "first-page": "291",
      "issue": "3",
      "journal-title": "Expert Opin Drug Metab Toxicol",
      "key": "546_CR33",
      "unstructured": "Cecchin E, De Mattia E, Toffoli G. Nuclear receptors and drug metabolism for the personalization of cancer therapy. Expert Opin Drug Metab Toxicol. 2016;12(3):291–306. https://doi.org/10.1517/17425255.2016.1141196.",
      "volume": "12",
      "year": "2016"
    },
    {
      "DOI": "10.2217/pgs-2016-0095",
      "author": "E De Mattia",
      "doi-asserted-by": "publisher",
      "first-page": "1547",
      "issue": "14",
      "journal-title": "Pharmacogenomics",
      "key": "546_CR34",
      "unstructured": "De Mattia E, Cecchin E, Roncato R, Toffoli G. Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. Pharmacogenomics. 2016;17(14):1547–71. https://doi.org/10.2217/pgs-2016-0095.",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.2217/pgs.13.214",
      "author": "E De Mattia",
      "doi-asserted-by": "publisher",
      "first-page": "2035",
      "issue": "16",
      "journal-title": "Pharmacogenomics",
      "key": "546_CR35",
      "unstructured": "De Mattia E, Dreussi E, Cecchin E, Toffoli G. Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects? Pharmacogenomics. 2013;14(16):2035–54. https://doi.org/10.2217/pgs.13.214.",
      "volume": "14",
      "year": "2013"
    },
    {
      "DOI": "10.1124/jpet.118.255018",
      "author": "DG Hu",
      "doi-asserted-by": "publisher",
      "first-page": "363",
      "issue": "3",
      "journal-title": "J Pharmacol Exp Ther",
      "key": "546_CR36",
      "unstructured": "Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma. J Pharmacol Exp Ther. 2019;368(3):363–81. https://doi.org/10.1124/jpet.118.255018.",
      "volume": "368",
      "year": "2019"
    },
    {
      "DOI": "10.1097/MOL.0b013e32832dd4b1",
      "author": "F Karpe",
      "doi-asserted-by": "publisher",
      "first-page": "333",
      "issue": "4",
      "journal-title": "Curr Opin Lipidol",
      "key": "546_CR37",
      "unstructured": "Karpe F, Ehrenborg EE. PPARdelta in humans: genetic and pharmacological evidence for a significant metabolic function. Curr Opin Lipidol. 2009;20(4):333–6. https://doi.org/10.1097/MOL.0b013e32832dd4b1.",
      "volume": "20",
      "year": "2009"
    }
  ],
  "reference-count": 37,
  "references-count": 37,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00546-9"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}